Revolution Medicines, Inc.

As such, this is encouraging to the oncologists who treat the problem and the patients who have it.

The medication is made by Revolution Medicines.

It's approved for patients who have already failed chemotherapy for pancreatic cancer.

When the data leading to the FDA approval was presented at a recent oncology conference, the audience applauded.

As such, this is encouraging to the oncologists who treat the problem and the patients who have it.

The medication is made by Revolution Medicines.

It's approved for patients who have already failed chemotherapy for pancreatic cancer.

When the data leading to the FDA approval was presented at a recent oncology conference, the audience applauded.

Governor Pritzker pushes data center legislation into the fall veto session.

And Crain's John Asplen joins me to go deeper on the fate of a breakthrough cancer drug from Revolution Medicines that was born here in Illinois.

The Chicago area is

still not in the top five biohubs in the country.

Make amazing happen.

Find out more at CDW.com slash Everpure.

Revolution Medicines is a company founded at the University of Illinois with a big new win under its belt.

Just receiving FDA approval last month for Raisin Q, a new drug to treat pancreatic cancer.

A breakthrough new drug is bringing fresh hope to pancreatic cancer patients and highlighting a dramatic shift in how Illinois keeps homegrown medical discoveries right here at home.

Crane's John Asplen reports the FDA recently approved RasenQ, a groundbreaking drug developed by Revolution Medicines that can double survival rates for patients with advanced pancreatic cancer.

The medicine targets tumor-causing proteins once thought to be completely untreatable, giving patients both more time and a better quality of life.

While the drug made national headlines, its roots trace back to an organic chemistry lab at the University of Illinois Urbana-Champaign led by Dr. Martin Burke.

But when Revolution Medicines launched a decade ago, local infrastructure couldn't keep it here.

The company moved its headquarters to California, making it another painful, what could have been, story for the region's biotech sector.

Now, local industry leaders say Illinois is finally positioned to break that pattern.

Yeah.

So I've been very privileged to be involved in the early to mid to late stage development of this in terms of the phase one and then the help design the phase three with multiple colleagues across the country and of course with the support of Revolution Medicines who sponsored and funded the study and also to be part of the steering committee with Dr. Walpin and Dr. Weinberg who oversaw the trial as it was conducted and provided insights and and involved in the dissemination of the outcome from the RASLU 302 trial and continuing to develop this drug and related drugs in pancreas cancer in various different disease settings.

And there's just huge interest in building on this in every setting in pancreas cancer, right, in the resected setting.

So people have undergone surgery, people who are potential candidates for surgery, people who don't have metastatic disease, and keeping in mind that the recent FDA approval is focused on metastatic disease, but there's about 50% of people with this diagnosis that don't have, at the time of their diagnosis, metastatic disease.